A COMPOSITION COMPRISING HUMANIZED ANTI-EGFR MAB H-R3 ANTIBODY AND TYPE I INF FOR USE IN TREATING CANCER

摘要

Summary of the invention: The present invention describes specific therapeutic compositions, which increase the efficacy of the therapeutic treatment using monoclonal antibodies against the Epidermal Growth Factor Receptor (EGFR) in a combination with type I IFNs.